Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial

This is a phase Ib study of anlotinib plus a programmed death-ligand 1 (PD-L1) inhibitor TQB2450 for platinum-resistant or -refractory ovarian cancer. Thirty-four patients are enrolled and receive treatment. The objective response rate (ORR) is 47.1%, and the disease control rate is 97.1%. The media...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Chun-Yan, Zhao, Jing, Yang, Fan, Xiong, Ying, Li, Rong, Huang, Yu, Wang, Jing, Liu, Chang, Bi, Xue-Han, Jin, Hai-Hong, Meng, Jin, Zhao, Wei-Hong, Zhang, Li, Wang, Ya-Fei, Zheng, Min, Huang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381412/
https://www.ncbi.nlm.nih.gov/pubmed/35858589
http://dx.doi.org/10.1016/j.xcrm.2022.100689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381412/
https://www.ncbi.nlm.nih.gov/pubmed/35858589
http://dx.doi.org/10.1016/j.xcrm.2022.100689

Ejemplares similares